A randomized phase II study of pulsatile high-dose sunitinib versus TAS-102 in patients with metastatic colorectal carcinoma (mCRC).
收藏NIAID Data Ecosystem2026-03-11 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2442614
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: A: TAS-102 (Lonsurf) 35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period.
B: Experimental: High Dose Intermittent Sunitinib 700 mg once every 2 weeks.
Primary outcome(s): The primary objective of this study is to improve progression free survival (PFS), of patients with metastatic colorectal carcinoma (mCRC) treated with high-dose sunitinib once every 2 weeks to 5 months, compared to the reported 2 months for TAS-102 monotherapy.
Study Design: Randomized controlled trial, Open (masking not used), Active, Parallel
创建时间：
2019-10-15
